860 related articles for article (PubMed ID: 23963793)
1. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
2. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
4. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
[TBL] [Abstract][Full Text] [Related]
5. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
6. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
8. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Geneen LJ; Dorée C; Estcourt LJ
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012349. PubMed ID: 36877640
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Gomber S; Jain P; Sharma S; Narang M
Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
[TBL] [Abstract][Full Text] [Related]
13. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Neufeld EJ
Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Schell LK; Rücker G; Motschall E; Fleeman N; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2014 Jun; 5(5):CD007477. PubMed ID: 24893174
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
17. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Padhani ZA; Gangwani MK; Sadaf A; Hasan B; Colan S; Alvi N; Das JK
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD011626. PubMed ID: 37975597
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
[TBL] [Abstract][Full Text] [Related]
20. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Sadaf A; Hasan B; Das JK; Colan S; Alvi N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD011626. PubMed ID: 29998494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
